Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
eli lilly
8
×
life sciences
national blog main
san francisco blog main
clinical trials
indiana blog main
indiana top stories
national top stories
san francisco top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
fda
cancer immunotherapy
deals
johnson & johnson
merck
startups
abbvie
alzheimer's disease
boehringer ingelheim
celgene
What
companies
8
×
bio
drug
roundup
new
approval
black
diamond
fda
ipo
leading
life
medicines
nash
news
price
science
therapeutics
therapies
week
year
abandoning
ago
alzheimer’s
approved
arena’s
arguments
baggage
big
biogen’s
biopharmaceutical
biotech
bounty
cancer
cig
class
clinic
comeback
commercialized
competitors
Language
unset
Current search:
biotech
×
companies
×
" eli lilly "
×
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M